NUVECTIS PHARMA INC. - COMMON STOCK

Nuvectis Pharma to Participate in a Fireside Chat at the 35th Annual Roth Conference

10 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

Nuvectis Pharma, Inc. Reports Fiscal Year 2022 Financial Results and Business Highlights

07 Mar 2023 07:00:31 By Nasdaq GlobeNewswire

Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800 at the 2023 ESMO Gynecological Cancers Congress

23 Feb 2023 07:00:02 By Nasdaq GlobeNewswire

Nuvectis Pharma Announces a Publication in The Journal of Experimental Medicine for NXP900 in an In-Vivo Model of Metastatic Castration Resistant Prostate Cancer (“mCRPC”) with Acquired Resistance to Enzalutamide, the Active Ingredient in Xtandi®

09 Feb 2023 07:00:01 By Nasdaq GlobeNewswire

Nuvectis Pharma Announces Collaboration with ENGOT and GOG Foundation to Conduct the NXP800 Phase 1b Clinical Trial in ARID1A-Mutated Ovarian Carcinoma in Europe and in the United States

04 Jan 2023 07:00:01 By Nasdaq GlobeNewswire

FDA Grants Fast Track Designation to Nuvectis Pharma's NXP800 for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma

01 Dec 2022 07:00:01 By Nasdaq GlobeNewswire

Nuvectis Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Highlights

08 Nov 2022 07:00:40 By Nasdaq GlobeNewswire

Nuvectis Phrama Announces Two Upcoming Poster Presentations at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

18 Oct 2022 07:00:50 By Nasdaq GlobeNewswire

Nuvectis Pharma, Inc. to Present at the Roth Inaugural Healthcare Opportunities Conference

03 Oct 2022 15:30:00 By Nasdaq GlobeNewswire

Nuvectis Pharma Announces Formation of a Scientific Advisory Board

28 Sep 2022 07:00:00 By Nasdaq GlobeNewswire

Nuvectis Pharma Announces Positive Data for NXP800 in a Preclinical Model of ARID1a-Mutated Gastric Carcinoma

13 Sep 2022 07:30:00 By Nasdaq GlobeNewswire

Nuvectis Pharma, Inc. to Present at Upcoming Investment Conferences

07 Sep 2022 07:30:01 By Nasdaq GlobeNewswire

Nuvectis Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Highlights

05 Aug 2022 07:00:00 By Nasdaq GlobeNewswire

Nuvectis Pharma, Inc. Announces Approximately $15.9 Million Private Placement

27 Jul 2022 07:00:01 By Nasdaq GlobeNewswire

Nuvectis Pharma Announces FDA Clearance of IND for NXP800

21 Jun 2022 07:15:00 By Nasdaq GlobeNewswire

Nuvectis Pharma Announces Positive Data for NXP900 in a Preclinical Model of Group 4 Medulloblastoma, A Type of Brain Cancer That Affects Predominantly Pediatric Patients

13 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

Nuvectis Pharma to Present in the H.C. Wainwright Global Investment Conference

20 May 2022 09:21:14 By Nasdaq GlobeNewswire

Nuvectis Pharma, Inc. Reports First Quarter 2022 Financial Results and Business Highlights

10 May 2022 07:30:01 By Nasdaq GlobeNewswire

Nuvectis Pharma Recaps Poster Presentation Highlights for NXP900 at the 2022 American Association for Cancer Research (AACR) Conference

13 Apr 2022 07:30:00 By Nasdaq GlobeNewswire

Nuvectis Pharma Recaps Oral Presentation Highlights for NXP800 at the 2022 American Association for Cancer Research (AACR) Conference

11 Apr 2022 07:30:00 By Nasdaq GlobeNewswire